The clinical course of COVID-19 in hematopoietic stem cell transplantation (HSCT) recipients

Background/aim: The disease caused by SARS-CoV-2 was named as COVID-19. There is as yet insufficient information about the effects of HSCT on the clinical course of COVID-19. In the present study, we aimed to investigate the clinical course of COVID-19 in patients who had undergone HSCT. Materials and methods: We analyzed baseline characteristics, clinical course and findings of COVID-19, hospitalization and death rates, overall survival, and case fatality rates of HSCT recipients diagnosed with COVID-19 retrospectively. Results: 57.6% of the patients underwent AHSCT, and 42.4% underwent allo-HSCT. 60.6%, 27.3%, and 12.1% of the patients had mild, moderate, and severe COVID-19 or critical illness, respectively. Overall, 45.5% were hospitalized, 12.1% required intensive care, and 9.1% necessitated invasive mechanical ventilation. The total CFR was 9.1% in HSCT recipients, 22.2% in patients with active hematologic malignancy, and 4.2% in patients without active hematologic malignancy. Conclusion: It can be concluded that mortality of HSCT recipients is lower in patients whose primary disease is in remission compared to ones that are not in remission. Further studies with larger group patients are needed in order to delineate the effects of COVID-19 on HSCT patients.Key words: Hematopoietic stem cell transplantation, bone marrow transplant, COVID-19

PDF

___

1. Guan WJ, Ni ZY, Hu Y, Liang WH, Ou CQ et al. Clinical characteristics of Coronavirus disease 2019 in China. New England Journal of Medicine 2020; 382 (18): 1708-1720. doi: 10.1056/NEJMoa2002032
2. Shah V, Ko Ko T, Zuckerman M, Vidler J, Sharif S et al. Poor outcome and prolonged persistence of SARS-CoV-2 RNA in COVID-19 patients with haematological malignancies; King’s College Hospital experience. British Journal of Haematology 2020; 190 (5): e279-e282. doi: 10.1111/bjh.16935
3. Haroon A, Alnassani M, Aljurf M, Ahmed SO, Shaheen M et al. COVID-19 post hematopoietic cell transplant, a report of 11 cases from a single center. Mediterranean Journal of Hematology and Infectious Diseases 2020; 12 (1): e2020070. doi: 10.4084/mjhid.2020.070
4. Ljungman P, Mikulska M, De la Camara R, Basak GW, Chabannon C et al. The challenge of COVID-19 and hematopoietic cell transplantation; EBMT recommendations for management of hematopoietic cell transplant recipients, their donors, and patients undergoing CAR T-cell therapy. Bone Marrow Transplantation 2020; 55 (11): 2071-2076. doi: 10.1038/s41409-020-0919-0
5. Sultan AM, Mahmoud HK, Fathy GM, Abdelfattah NM. The outcome of hematopoietic stem cell transplantation patients with COVID-19 infection. Bone Marrow Transplantation 2021; 56: 971-973. doi: 10.1038/s41409-020-01094-9
6. Çalık Başaran N, Uyaroğlu OA, Telli Dizman G, Özışık L, Şahin TK et al. Outcome of noncritical COVID-19 patients with early hospitalization and early antiviral treatment outside the ICU. Turkish Journal of Medical Sciences 2020; 51: 411-420. doi: 10.3906/sag-2006-173
7. Varma A, Kosuri S, Ustun C, Ibrahim U, Moreira J et al. COVID-19 infection in hematopoietic cell transplantation: age, time from transplant and steroids matter. Leukemia 2020; 34 (10): 2809-2812. doi: 10.1038/s41375-020-01019-x
8. Kanellopoulos A, Ahmed MZ, Kishore B, Lovell R, Horgan C et al. COVID-19 in bone marrow transplant recipients: reflecting on a single centre experience. British Journal of Haematology 2020; 190 (2): e67-e70. doi: 10.1111/bjh.16856
9. Coll E, Fernández-Ruiz M, Sánchez-Álvarez JE, MartínezFernández JR, Crespo M et al. COVID-19 in transplant recipients: the Spanish experience. American Journal of Transplantation 2021; 21 (5): 1825-1837. doi: 10.1111/ajt.16369
10. Altuntas F, Ata N, Yigenoglu TN, Bascı S, Dal MS et al. COVID-19 in hematopoietic cell transplant recipients. Bone Marrow Transplantation 2021; 56 (4): 952-955. doi: 10.1038/ s41409-020-01084-x
11. Sharma A, Bhatt NS, St Martin A, Abid MB, Bloomquist J et al. Clinical characteristics and outcomes of COVID-19 in haematopoietic stem-cell transplantation recipients: an observational cohort study. The Lancet Haematology 2021; 8 (3): e185-e193. doi: 10.1016/s2352-3026(20)30429-4
12. Baranovich T, Wong SS, Armstrong J, Marjuki H, Webby RJ et al. T-705 (favipiravir) induces lethal mutagenesis in influenza A H1N1 viruses in vitro. Journal of Virology 2013; 87 (7): 3741-3751. doi: 10.1128/jvi.02346-12
13. Kiso M, Takahashi K, Sakai-Tagawa Y, Shinya K, Sakabe S et al. T-705 (favipiravir) activity against lethal H5N1 influenza A viruses. Proceedings of the National Academy of Sciences 2010; 107 (2): 882-887. doi: 10.1073/pnas.0909603107